Physicians should not prescribe ADD drugs to healthy people

Physicians in Canada should consider refusing to prescribe cognitive enhancement medications—also used to treat attention deficit disorder (ADD)—to healthy patients, states an analysis article in CMAJ (Canadian Medical Association Journal). Lack of evidence for benefits and possibility of harm, limited health care resources and professional integrity of physicians are reasons why this use is not acceptable.

Prescription stimulants such as methylphenidate and dextroamphetamine are often used by people for "cognitive enhancement" to increase focus, concentration and memory. Because these drugs are available in Canada by prescription only, people must request them from their doctors.

"Physicians are important stakeholders in this debate, given the risks and regulations of prescription drugs and the potential for requests from patients for cognitive enhancers," writes Dr. Eric Racine, Institut de recherches cliniques de Montréal and Université de Montréal, with coauthors.

People take prescription stimulants to perform better in school or at work. Prevalence rates of cognitive enhancer use by university students ranges from 1% to 11% in some studies. Risks to taking stimulants include cardiovascular harm, dependence and psychosis. Current evidence has not shown that the desired benefits of enhanced are achieved with these substances.

"With uncertain benefits and clear harms, it is difficult to support the notion that physicians should prescribe a medication to a healthy individual for enhancement purposes," adds Dr. Racine with Cynthia Forlini, two coauthors of the paper.

Because physicians in Canada provide prescriptions through a publicly funded health care system with expanding demands for care, prescribing cognitive enhancers may not be an appropriate use of resources.

"Given the current state of limited evidence on medical, scientific, social and ethical aspects of cognitive enhancement, we call for greater attention to its appropriateness within existing Canadian health care systems," the authors conclude.

More information: Paper: www.cmaj.ca/lookup/doi/10.1503/cmaj.121508

add to favorites email to friend print save as pdf

Related Stories

Time to address stimulant abuse on our campuses

Sep 06, 2011

Universities and colleges need to do more to protect young adults from the dangers of illicit stimulant use and to educate them about harms, argue the authors of an editorial in CMAJ (Canadian Medical Association Journal).

Prescriptions for teens and young adults on the rise

Nov 29, 2010

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments